What's Hot

    M&G agrees two bulk purchase annuity deals totalling $760m

    21 September 2023

    ELSA Welcomes New Executive Board Members

    19 September 2023

    Editor’s Letter – Volume 2, Issue 9, September 2023

    15 September 2023
    Facebook Twitter Instagram
    Instagram LinkedIn Twitter
    Life Risk News
    • Home
    • Features

      Spotlight Falls on US Life Insurers’ Private Debt Investments

      14 September 2023

      The US Now The Last Remaining Traded Life Policy Market

      14 September 2023

      Re-Visiting the SEC Life Settlements Task Force More Than a Decade Later

      14 September 2023

      Generative AI Set to Transform Life Insurance Industry

      14 September 2023

      Q&A: David Blake, Professor of Finance & Director of Pensions Institute, Bayes Business School

      14 September 2023
    • Commentary

      The Critical Nature of Life Insurance Policy Due Diligence in the Life Settlement Asset Class

      14 September 2023

      Covid-19 Excess Mortality Analysis

      14 September 2023

      The Insurance Regulator Takes a Look at Funded Reinsurance

      10 August 2023

      Life Settlement Apocrypha

      10 August 2023

      UK Closed Life Funds – A Secret Returns Goldmine?

      12 July 2023
    • Events
    • Magazine
    • News

      M&G agrees two bulk purchase annuity deals totalling $760m

      21 September 2023

      ELSA Welcomes New Executive Board Members

      19 September 2023

      Prudential Financial and Warburg Pincus back new annuity reinsurer

      14 September 2023

      Ford UK pension scheme signs $450m partial buy-in deal

      14 September 2023

      European Life Settlement Association (ELSA) Hosts Successful Secondary Life Markets Conference 2023

      13 September 2023
    Subscribe
    Life Risk News
    Home»Commentary»Have We Learned from The Past or Are We Doomed To Repeat It?

    Have We Learned from The Past or Are We Doomed To Repeat It?

    Commentary 16 November 2022Vince GranieriBy Vince Granieri
    Twitter LinkedIn Email
    Covid-19 Life Settlements
    Share
    Twitter LinkedIn Email

    Like many things in life, longevity markets have followed broad cycles. Industry veterans will remember a particularly painful turn in late 2008, when new information regarding life settlement population mortality was reflected in industry life expectancies. In response, some industry players adapted better than others. In 2019, there was another market downturn, and those who learned from 2008 were rewarded.

    Covid-19 has provided an opportunity for the industry to demonstrate what we have learned – but will we? We have been recently inundated with data about Covid-19 and its effects on mortality. Some of this information is applicable to life settlements, but some is not. Yet there is no broad recognition of that fact. This paper presents a general overview of the situation. Specific details and calculations are beyond its scope but are available upon request.

    The Issue

    When the industry initially shifted from viatical settlements for HIV patients to impaired seniors, folks presumed that life settlement population mortality would resemble that of the life insurance population and life insurance mortality tables would properly reflect this. That made sense, as both populations underwent the life insurance underwriting process and owned policies. But it was not a good assumption and it led to a market crash in 2008, for three main reasons as outlined in a paper I wrote in 2011:

    1.            The insured had better information about their health than was contained in their medical records and they would select against the investor, selling if their health was better than expected and vice-versa.

    2.            The life settlement industry, with its fragmented sources of data, did not have statistically significant data bases to prove this phenomenon until 2008.

    3.            Use of the 2001 VBT without adjusting for mortality improvement, would have led to issues even if these two populations had very similar mortality.

    The lessons of 2008 included understanding that the life settlement population is somewhat unique and certainly different from the US general population and the US life insurance population, and it was necessary to assume future mortality improvement in valuing policies.

    Current Environment

    Covid-19 affected nearly every element of life for nearly everyone. Increased mortality was observed among most populations. It was critical for both investors and policyowners in life settlements to assess the proper response. Given the uncertainty of the situation, initial responses from all parties were to delay or forego transactions. With the rapid resolution and binary outcome of Covid-19 infection, this was a perfectly logical response. Over time, two important issues emerged – the lasting effect of Covid-19 on mortality rates, and the emergence of so-called ‘long Covid’ (cases where victims survived but symptoms remained). Given the widespread impact of Covid-19, studies were plentiful and prioritized. It was only a matter of time before these studies were completed. This is the news that everyone was waiting for.

    Information Overload

    As I looked at the myriad of information being disseminated, it was difficult to hold back from leaping into action. Soon, statistics were being widely quoted in industry gatherings about Covid-19’s effects. But did we learn from the past? Perhaps it’s too early to tell. Let’s review the important lessons from the past.

    The life settlement population is different from the US general population and the US life insurance population. The studies are clear – Covid-19 increased mortality by 15-20%. A closer look reveals that this applies to the general population, not the life settlement population. Further, by isolating Covid-19 as a cause of death, the fact that deaths from another cause, the flu, virtually disappeared. The Society of Actuaries published a study that suggested that the life insurance population suffered 15% excess mortality from Covid-19. Again, this is not our population in life settlements. The SOA study did provide insight that might be useful for life settlements. At ages above 65, excess mortality was far lower than the rate for the overall life insurance population.

    But when we look at data from life settlements’ populations, the Covid-19 effect is negligible. In the Predictive Resources data base, raw mortality rates hardly moved throughout 2020 and 2021. In fact, the 2017-18 flu caused a bigger mortality ripple in our data. Other industry participants have echoed this finding. Yet the talking heads at industry meetings still quote either population data or life insurance data when talking about Covid-19’s effect on mortality. You know better than to listen. Someone may know the general population inside and out, but if they don’t understand the life settlement population, they are of little help.

    Long Covid. I have also seen and heard quoted, studies from respected institutions of higher learning that place the percentage of Covid-19 cases that will eventually become long Covid-19 cases at 30-40%. Those figures are shocking until you carefully read those studies and realize they define long Covid-19 as symptoms lasting over 2-3 weeks. Again, the lessons learned from the past can help us today.

    Mortality improvement. Covid-19 has hampered researchers studying mortality improvement in the general population, as it presents a one-time blip that may or may not continue. Since life settlement populations are so small, it’s not possible to extract statistically significant mortality improvement statistics. In those instances, give careful consideration to other populations, and take care to not rely too heavily on the conclusions. Recent research by Predictive Resources suggests both age and birth era are appropriate independent variables from which to derive mortality improvement statistics. Given recent trends in obesity and other factors, it is quite possible that, for the first time in centuries, mortality may no longer be improving.

    Conclusion

    The impact of Covid-19, both short and long term is a vital concern for life settlement industry participants. Properly judging its impact is a key task that is made more difficult by the myriad of data that is being disseminated, much of which needs to be judiciously evaluated in order to avoid similar mistakes of bygone eras in life settlements.

    Vince Granieri is CEO At Predictive Resources

    Life Settlements Volume 1 Issue 7 - November 2022
    Share. Twitter LinkedIn Email

    Related Posts

    The Critical Nature of Life Insurance Policy Due Diligence in the Life Settlement Asset Class

    14 September 2023

    Covid-19 Excess Mortality Analysis

    14 September 2023

    The Insurance Regulator Takes a Look at Funded Reinsurance

    10 August 2023

    Life Settlement Apocrypha

    10 August 2023

    Comments are closed.

    Most Popular

    Spotlight Falls on US Life Insurers’ Private Debt Investments

    14 September 2023

    The US Now The Last Remaining Traded Life Policy Market

    14 September 2023

    Re-Visiting the SEC Life Settlements Task Force More Than a Decade Later

    14 September 2023

    Generative AI Set to Transform Life Insurance Industry

    14 September 2023
    Ad

    Your trusted source for capital markets participation in Life Risk

    Twitter Instagram LinkedIn
    Life Risk
    • About Life Risk News
    • Get In Touch
    • Our Team
    • Copyright Notice
    • Privacy Policy
    • Sitemap
    Coverage
    • Home
    • Features
    • Events
    • Commentary
    Subscribe

    Type above and press Enter to search. Press Esc to cancel.

    We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept All”, you consent to the use of ALL the cookies. However, you may visit "Cookie Settings" to provide a controlled consent.
    Cookie SettingsAccept All
    Manage consent

    Privacy Overview

    This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
    Necessary
    Always Enabled
    Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
    CookieDurationDescription
    cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
    cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
    cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
    cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
    cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
    viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
    Functional
    Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
    Performance
    Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
    Analytics
    Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
    Advertisement
    Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
    Others
    Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
    SAVE & ACCEPT